CD30 aptamer-functionalized PEG-PLGA nanoparticles for the superior delivery of doxorubicin to anaplastic large cell lymphoma cells.

Abstract

Nanoparticles (NPs) conjugated with aptamers have been extensively in recent years, which can efficiently target cancer cells that improve the therapeutic effect. Aptamers (Apt) are small oligonucleotide molecule ligands have specific high-affinity. In this work, we developed a PEG-PLGA nanoparticles (NPs) encapsulated with doxorubicin. The NPs were modified with C2NP, a ssDNA aptamer specifically binding to CD30 protein which was over expressed in anaplastic large cell lymphoma (ALCL) cells. PEG-PLGA nanoparticles (NPs) were formed by nanoprecipitation and loaded with doxorubicin, further conjugated C2NP aptamer via an EDC/NHS technique. Obtained results demonstrated that the targeted agent was successfully conjugated confirming by Urea PAGE and XPS. The physicochemical properties of Apt-DOX-NPs like particle size at 168.07 ± 2.72 nm and zeta potential at -30.76 ± 0.153 mV. The time of the release drugs was efficiently increased in targeted formulations and showed higher accumulation in ALCL cells than non-targeted system. Findings from this work demonstrated the potential efficacy of C2NP-functionalized nanoparticles for a therapy in ALCL.

• Authors: Xiao Luo, Yulian Yang, Fanhui Kong, Long Zhang, Kun Wei
• Journal: International journal of pharmaceutics (Int J Pharm) Vol. 564 Pg. 340-349 (Jun 10 2019) ISSN: 1873-3476 [Electronic] Netherlands
• PMID: 31002934 (Publication Type: Journal Article)
• Copyright: Copyright © 2019 Elsevier B.V. All rights reserved.

Chemical References

• Antineoplastic Agents
• Aptamers, Nucleotide
• Ki-1 Antigen
• Polyesters
• polyethylene glycol-poly(lactide-co-glycolide)
• Polyethylene Glycols
• Doxorubicin

Topics

• Antineoplastic Agents (administration & dosage)
• Aptamers, Nucleotide (administration & dosage)
• Cell Line, Tumor
• Cell Survival (drug effects)
• Doxorubicin (administration & dosage)
• Drug Delivery Systems
• Humans
• Ki-1 Antigen
• Lymphoma, Large-Cell, Anaplastic (drug therapy)
• Nanoparticles (administration & dosage)
• Polyesters (administration & dosage)
• Polyethylene Glycols (administration & dosage)